Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Taskus Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $295.73 (market cap $8.04B), while Taskus Inc trades at $5.92 (market cap $530.70M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 15.1× Taskus Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| BIO | TASK | |
|---|---|---|
Market Cap | $8.04B | $530.70M |
Sector | Health | Technology |
52-Week High | $339.75 | $18.21 |
52-Week Low | $241.71 | $4.57 |
Enterprise Value | $7.85B | $926.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
TaskUs (TASK) trades at $5.62, up 3.88% with strong valuation metrics including P/E of 4.97 and P/S of 0.43. The company reported Q1 2026 earnings miss but maintains solid fundamentals with 8.7% net margin and 26.52% ROE. Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages. Recent CFO appointment and robotaxi survey highlight growth initiatives.
The stock appears undervalued with 69% upside to consensus target of $9.50. Strong cash flow generation and improving debt-to-asset ratio (22.96% in 2025) support bullish case. Risks include competitive pressures and earnings volatility. Analyst consensus leans bullish with 55% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
